Effect of Nano-Curcumin in Juvenile Idiopathic Arthritis

Evaluation of the Efficacy of Nanomicelle Curcumin Formulation in Children with Juvenile Idiopathic Arthritis(JIA)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191221045837N1

Enrollment

Registered

2020-09-28

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with Juvenile Idiopathic Arthritis(JIA). Juvenile arthritis

Interventions

Intervention 1: Intervention group: In the intervention group, patients with JIA will receive standard JIA treatment (according to the ACR 2019 Guideline) along with 40 mg daily curcumin syrup for 3 m

Eligibility

Sex/Gender

All

Age

6 Years to 16 Years

Inclusion criteria

Inclusion criteria: All children between 6 and 16 years old referring to Akbar hospital Rheumatology subspecialty clinic who diagnosed suffering JIA according to ACR Guidline1 Obtain patient/patient's parents informed consent

Exclusion criteria

Exclusion criteria: Children under 6 years old and or teenagers older than 16 years old Child with a history of underlying diseases including heart, kidney, liver, bile, digestive and or reumatoid ( any kind of reumatoid diseases except JIA) diseases simultaneous Consuming anticoagulant medicines like warfarin or anti-platelet medicines by patient Diabetic patients

Design outcomes

Primary

Measure	Time frame
In all patients, the severity of JIA disease will be assessed and recorded at baseline, at the end of the first month and at the end of the third month of treatment using the ACR-Pedi30 Score. The main factors examined in the ACR-Pedi30 Score are: 1- Physician evaluation of the disease activity (PhGA) 2- Evaluation of the patient or parents of the child from their child's health 3- Evaluation of joint function 4- Number of joints involved 5- Number of joints with limitations in Range of motion (ROM) 6- ESR measurement. Timepoint: At baseline, at the end of the first month and the end of the third month of treatment. Method of measurement: 1- Physician evaluation of the disease activity (PhGA) 2- Evaluation of the patient or parents of the child from their child's health 3- Evaluation of joint function 4- Number of joints involved 5- Number of joints with limitations in Range of motion (ROM) 6- ESR measurement.	—

Measure

Time frame

In all patients, the severity of JIA disease will be assessed and recorded at baseline, at the end of the first month and at the end of the third month of treatment using the ACR-Pedi30 Score. The main factors examined in the ACR-Pedi30 Score are: 1- Physician evaluation of the disease activity (PhGA) 2- Evaluation of the patient or parents of the child from their child's health 3- Evaluation of joint function 4- Number of joints involved 5- Number of joints with limitations in Range of motion (ROM) 6- ESR measurement. Timepoint: At baseline, at the end of the first month and the end of the third month of treatment. Method of measurement: 1- Physician evaluation of the disease activity (PhGA) 2- Evaluation of the patient or parents of the child from their child's health 3- Evaluation of joint function 4- Number of joints involved 5- Number of joints with limitations in Range of motion (ROM) 6- ESR measurement.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZinat Heidari

Mashhad University of Medical Sciences

heidarizn@mums.ac.ir+98 51 3180 1584

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026